Lunai Bioworks achieves complete regression of primary, metastatic pancreatic tumors in preclinical

 Lunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefense company, has announced a major scientific breakthrough: its next-generation immune cell therapy led to complete regression of both primary and metastatic pancreatic tumors in humanized mouse models.

The study was published in a new Brief Report in Vaccines on November 2, 2025. The peer-reviewed Brief Report details the development of a second-generation, clinical-grade DC construct that achieved complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models. Pancreatic cancer is one of the deadliest cancers, often diagnosed late and resistant to conventional treatments. Lunai's therapy uses engineered dendritic cells — specialized immune cells created from stem cells — that are genetically enhanced to activate the body's immune system against cancer. This publication details a second-generation, clinical-compliant version of this platform, with the provided evidence critical in advancing ongoing partnering conversations for the therapy.

The study was published in a new Brief Report in Vaccines on November 2, 2025. The peer-reviewed Brief Report details the development of a second-generation, clinical-grade DC construct that achieved complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models. Pancreatic cancer is one of the deadliest cancers, often diagnosed late and resistant to conventional treatments. Lunai's therapy uses engineered dendritic cells — specialized immune cells created from stem cells — that are genetically enhanced to activate the body's immune system against cancer. This publication details a second-generation, clinical-compliant version of this platform, with the provided evidence critical in advancing ongoing partnering conversations for the therapy.

https://finance.yahoo.com/news/lunai-bioworks-achieves-complete-regression-142200220.html

Bio-Techne misses quarterly sales estimates on weak biotech demand

 Biotech firm Bio-Techne missed its first-quarter revenue estimates on Wednesday, hurt by sluggish demand for its products amid soft biotech funding environment in China.

Shares of the Minneapolis, Minnesota-based company, which develops products used in medical research, drug development and diagnostics, were down nearly 10% premarket following the results.

"During the quarter, we observed encouraging signs of stabilization in our U.S. academic end-market and continued strength from large pharmaceutical customers, while funding headwinds persisted for emerging biotech companies," CEO Kim Kelderman said.

However, peers Thermo Fisher and Danaher flagged renewed demand for their services as pharmaceutical firms ramp up drug development and manufacturing in the U.S. while navigating President Donald Trump's shifting policies.

Bio-Techne said last quarter it expects uncertainty related to Trump's tariff and academic funding policies to spill into fiscal 2026 and create pressure on its performance.

The company posted adjusted profit per share of 42 cents for the quarter ended September 30, in line with analysts' average estimate of 42 cents, according to data compiled by LSEG.

Its quarterly revenue came in at $286.6 million, missing estimates of $291.2 million.

Sales at its largest protein sciences unit, which develops and manufactures biological compounds used for research and diagnostics, fell 1% to $202.2 million during the quarter.

Quarterly revenue from its diagnostics and genomics unit, which manufactures tools and compounds used to make therapeutics and vaccines, fell 4% to $79.5 million.

https://www.msn.com/en-us/money/markets/bio-techne-misses-quarterly-sales-estimates-on-weak-biotech-demand/ar-AA1PQXbF

NYC business leader fears 'lawless society' after Mamdani win

 Billionaire grocery chain owner John Castimatidis expressed concerns following New York City's historic mayoral race that the Big Apple could become "lawless" under Mayor-elect Zohran Mamdani's leadership.

Voters on Tuesday chose Mamdani, a self-described democratic socialist who defeated former New York Gov. Andrew Cuomo, to become the city's 111th mayor.

Specifically, Castimatidis told FOX Business that he is worried that Mamdani will appoint judges that are too lenient and that he will reduce the city's police force.

FOX Business reached out to Mamdani's team for comment.

In the months leading up to Tuesday's election, Catsimatidis repeatedly threatened to pull his grocery store chain, Gristedes, out of the city in response to Mamdani's plans to create a network of city-owned grocery stores to drive down food costs. While he is backtracking on the threats to close or sell Gristedes locations, he said he wants to lessen his company’s exposure.

Surging food prices was one of the central themes of Mamdani's campaign. His solution to combat this was to create a network of city-owned grocery stores "focused on keeping prices low, not making a profit," according to his campaign's website.

Mamdani claimed that without having to pay rent or property taxes, the stores "will reduce overhead and pass on savings to shoppers." The stores would also buy and sell at wholesale prices, centralize warehousing and distribution and partner with local neighborhoods on products and sourcing, according to Mamdani's campaign website. 

John Catsimatidis owns New York City grocery chain Gristedes. (Fox News)

In a March interview, Mamdani estimated that a pilot program for this plan would cost $60 million to execute, but he argued the city is set to spend more than double that on corporate supermarkets.

A National Grocers Association spokesperson previously told FOX Business that a better solution to lower food costs is "enforcing existing antitrust laws to spur healthy competition among independent grocers and big-box chains." 

"We urge public officials at all levels of government to direct resources toward enforcing the Robinson-Patman Act, cracking down on price discrimination and monopolistic leverage, and to collaborate with state and federal agencies to break down barriers on swipe fees and regulatory burdens," the spokesperson said. This will "empower independent grocers and strengthen food ecosystems more sustainably than launching government-run stores."

The Robinson-Patman Act was enacted in 1936 and prohibits price discrimination that could harm competition.

https://www.foxbusiness.com/lifestyle/nyc-business-leader-fears-lawless-society-after-zohran-mamdani-wins-mayoral-election